drugset

drugset / Trial / NCT05715632

New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX

NCT05715632 ↗

Unknown 46 enrolled Tang-Du Hospital

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of carelizumab combined with XELOX regimen in neoadjuvant treatment of locally advanced resectable gastric cancer

Timeline

Start: 2023-02-01
Primary completion: 2024-03-01
Completion: 2025-03-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	—	—

Indications